Literature DB >> 16557706

Detection of Antibody-Producing Cells of Mice Injected with Antigens of Neisseria meningitidis.

D G Evans1.   

Abstract

The technique of Jerne et al. was adapted to the study of the antibody response of mice to Neisseria meningitidis antigens. The mice were inoculated with heated group A bacteria or antigen concentrated from their culture fluid. Sheep erythrocytes were coated with bacterial lysate or culture fluid. These antigens were shown by immune hemolysis to be group-specific and appeared to be of identical specificity. The plaque-forming cell (PFC) response obtained with either antigen was dosedependent over a range of 10 to 300 mug per mouse. However, the maximum response, reached at 4 days, was quite low. The number of PFC per 10(6) nucleated cells, elicited by the heated bacteria and culture fluid, was 15 and 7, respectively. The number of PFC declined rapidly after the peak. A second injection of heated bacteria, given 18 days after the first injection, elicited a more rapid but otherwise similar reaction, apparently involving the production of only immunoglobulin M antibodies. No hemolytic antibodies were demonstrated in the sera of these mice. The passive hemolytic plaque assay here described provided the sensitivity necessary to study the details of the antibody response of mice to meningococcal antigen.

Entities:  

Year:  1970        PMID: 16557706      PMCID: PMC415870          DOI: 10.1128/iai.1.2.151-156.1970

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  11 in total

1.  The specific hapten of group C (group II alpha) meningococcus. I. Preparation and immunological behavior.

Authors:  R G WATSON; H W SCHERP
Journal:  J Immunol       Date:  1958-10       Impact factor: 5.422

2.  EXPERIMENTAL MENINGOCOCCAL INFECTION IN MICE.

Authors:  C P Miller
Journal:  Science       Date:  1933-10-13       Impact factor: 47.728

3.  The plaque test for the demonstration of antibodies against the enterobacterial common antigen produced by spleen and lymph node cells.

Authors:  G Domingue; E Neter
Journal:  Immunology       Date:  1967-12       Impact factor: 7.397

4.  Use of an antiglobulin serum to detect cells producing antibody with low haemolytic efficiency.

Authors:  D W Dresser; D H Wortis
Journal:  Nature       Date:  1965-11-27       Impact factor: 49.962

5.  19S antibody production against soluble lipopolysaccharide antigens by individual lymphoid cells in vitro.

Authors:  G Möller
Journal:  Nature       Date:  1965-09-11       Impact factor: 49.962

6.  Critical variables of the Jerne plaque technique as applied to rodent antibody-forming systems responding to heterologous red cell antigens.

Authors:  K F Hübner; N Gengozian
Journal:  J Immunol       Date:  1969-01       Impact factor: 5.422

7.  Assay of spleen cells forming antibodies to O-antigens of Salmonellae.

Authors:  A L Olitzki
Journal:  Proc Soc Exp Biol Med       Date:  1968-12

8.  Simplified method for the production of carbohydrate antigen from Neisseria meningitidis.

Authors:  E Weiss; J L Long
Journal:  Appl Microbiol       Date:  1969-11

9.  A somatic antigen vaccine for the prevention of meningococcal cerebrospinal meningitis.

Authors:  L Greenberg; M Y Cooper
Journal:  Bull World Health Organ       Date:  1965       Impact factor: 9.408

10.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  2 in total

1.  Response of mice to injection of ribosomal fraction from group B Neisseria meningitidis.

Authors:  D W Thomas; E Weiss
Journal:  Infect Immun       Date:  1972-09       Impact factor: 3.441

2.  Cellular Response of the Rabbit Eye to Primary Intravitreal Injection of Neisseria meningitidis.

Authors:  J F Pribnow; J M Hall; D Bradley; N A Vedros
Journal:  Infect Immun       Date:  1971-06       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.